[1] Leblanc E, Narducci F, Ferron G, et al. Indications and teaching of fertility preservation in the surgical management of gynecologic malignancies: European perspective[J]. Gynecol Oncol, 2009,114: 532-536. [2] Rodriguez-Wallberg KA, Oktay K.Options on fertility preservation in female cancer patients[J]. Cancer Treat Rev,2012,38:354-361. [3] Fleming GF, Ronnett BM, Seidman J. Epithelial ovarian cancer[M]// Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology. 5th ed. Philadelphia: Lippincott Williams & Wikins,2009:763-836. [4] Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA of IC invasive epithelial ovarian cancer treated with fertility-sparing therapy[J]. Gynecol Oncol, 2002, 87:1-7. [5] Trimbos JB, van der Burg ME. Adjuvant chemotherapy in patients operated on for early ovarian carcinoma[J]. Ned Tijdschr Geneeskd, 2004,148(18):874-878. [6] Lu KH, Skates S, Bevers TB, et al. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA)[J]. J Clin Oncol, 2010,28(Suppl 15): 2003. [7] Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting[J]. Gynecol Oncol, 2011,121:487-491. [8] Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass[J]. Obstet Gynecol, 2011,118:208-288. [9] Du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J]. Ann Oncol, 2005,16 (Suppl 8 ):viii7-viii12. [10] Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients[J]. J Natl Cancer Inst, 2006,98:172-180. [11] Giede KC, Kieser K, Dodge J, et al. Who should operate on patients with ovarian cancer:an evidence-based review [J].Gunecol Oncol, 2005,99:447-461. [12] Martinez A, Poilblanc M, Ferron G, et al. Fertility-preserving surgical procedures, techniques[J]. Best Pract Res Clin Obstet Gynaecol, 2012,26:407-424. [13] Jun Hu, Li-rong Zhu, Zhi-qing Liang, et al. Clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma[J]. Biomed Biotechnol, 2011, 12(10):787-795. [14] Park J, Kim D, Suh D, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes[J]. Gynecol Oncol, 2008,110: 345-353. [15] Stier EA, Barakat RR, Curtin JP, et al. Laparotomy to complete staging of presumed early ovarian cancer[J]. Obstet Gynecol, 1996,87:737-740. [16] Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer[J]. Cancer, 2009,115:4118-4126. [17] Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer[J]. J Clin Oncol, 1996,14:1718-1729. [18] Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy[J]. N Engl J Med,2005,353(3):318-321. [19] Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer[J]. Cancer Control, 2002,9:466-472. [20] Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma[J]. Cancer, 2006,106:514-523. [21] Morice P, Leblanc E, Rey A, et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Socie′te′ Franc aise d' Oncologie Gyne′cologique) [J]. Hum Reprod, 2005,20(5):1379-1385. [22] Ramez N, Eskander, Leslie M, et al. Fertility preserving options in patients with gynecologic malignancies[J]. Am J Obstet Gynecol, 2011, 103:110-117. [23] Satoh T, Hatae M, Watanabe Y, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection[J]. J Clin Oncol, 2010, 28:1727-1732. [24] Lalwani N, Anampady KPS, Vikram R, et al. Current update on borderline ovarian neoplasms[J]. AJR, 2010,194: (2):330-336. [25] 彭芝兰.复发性卵巢上皮交界性肿瘤的诊治[J].中国实用妇科与产科杂志,2012,28(5): 340-344. [26] Jeong-Yeol Park, Dae-Yeon Kim, Jong-Hyeok Kim, et al. Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery[J]. Gynecol Oncol, 2009,113:75-82. [27] Joo-Hyun Nam. Borderline ovarian tumors and fertility[J].Current Opinion in Obstetrics and Gynecology,2010,22:227-234. [28] Lenhard MS, Mitterer S, Kümper C, et al. Long-term follow-up after ovarian borderline tumor: Relapse and survival in a large patient cohort[J]. Eur J Obstet Gynecol Reprod Biol, 2009,145(2):189-194. [29] Uzan C,Kane A,Rey A, et al. Outcomes after conservative treatment of advancedstage serous borderline tumors of the ovary[J]. Ann Oncol, 2010,21:55-60. [30] Morris RT, Gershenson DM, Silva EG,et al. Outcome and reproductive function after conservative surgery for borderline ovarian tumors[J]. Obstet Gynecol,2000,95(4):541-547. [31] Fotopoulou C, Schumacher G, Joerg C, et al. Systematic evaluation of the intraoperative tumor pattern in patients with borderline tumor of the ovary[J]. Int J Gynecol Cancer, 2009, 19(9):1550-1555. [32] Ren Jie, Peng Zhilan. A clinicopathologic Multivariate analysisi affecting recurrence of borderline ovarian tumors[J]. Gynecol Oncol, 2008,110:162-167. [33] Laurent I, Uzan C, Gouy S, et al.Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern[J]. Ann Surg Oncol,2008,15(12):3561-3566. [34] Laurent I, Uzan C, Gouy S, et al. Results after conservative treatment of serous borderline tumours of the ovary with stromal microinvasion but without micropapillary pattern[J]. BJOG,2009 ,116(6):860-862. |